GMM Pfaudler Q2 FY27 Earnings Call Transcript Released
GMM Pfaudler released its Q2 FY27 earnings call transcript. The company achieved record order inflow of ₹1,200 crore in Q2 FY27, with India contributing ₹483 crore. A European restructuring program is underway to address losses, with manufacturing shifting to Poland. FY27 revenue is projected to grow double-digit, with reported EBITDA margins of 10-11%.
The announcement includes details on record order inflows, restructuring plans for European operations, and financial performance, which are all material information for investors. The forward-looking statements and guidance also indicate a significant impact on future expectations.
The company reported record order inflows, strong revenue growth, and provided a positive outlook for FY27, despite ongoing restructuring in Europe. The management expressed confidence in future growth and profitability.
GMM Pfaudler Limited has released the transcript of its earnings conference call for the quarter and half-year ended September 30, 2026. The call, conducted on November 5, 2026, featured insights from Managing Director Mr. Tarak Patel, Group CEO Mr. Gregory Gelhaus, and Group CFO Mr. Ankit Nayyar.
During the call, management highlighted a record quarterly order inflow exceeding ₹1,000 crore for consecutive quarters, reaching ₹1,200 crore, with India contributing ₹483 crore – more than double sequentially. This growth was broad-based across all four business divisions, driven by investments in pharmaceuticals (especially CDMO and peptides), petrochemicals, fertilizers, defense, energy, and power sectors.
The company also announced a restructuring program for its European operations to address structural profitability challenges. Loss-making European entities reported an EBITDA loss of approximately ₹43 crore in H1 FY27. The restructuring involves aligning costs with business volumes, improving manufacturing efficiency, and shifting manufacturing activities to Poland. The UK facility has been closed, and workforce reduction measures have been implemented in Germany.
For FY 2027, GMM Pfaudler expects double-digit revenue growth and a reported EBITDA margin of 10%-11%. Adjusted EBITDA margins for profitable segments are projected at 14%-15%. The company aims to improve financial flexibility through debt reduction, having repaid approximately ₹116 crore of net debt in H1 FY27.
Key financial highlights for Q2 FY27 included a record order intake of ₹1,198 crore, up 36% year-on-year, and consolidated revenue of ₹1,065 crore, up 18% year-on-year. For H1 FY27, order intake was a record ₹2,204 crore, up 17% year-on-year, and revenue was ₹1,989 crore, up 17% year-on-year. Reported EBITDA for Q2 FY27 was ₹110 crore, with an adjusted EBITDA of ₹139 crore (15.9% margin) excluding loss-making entities. Profit after tax for the quarter stood at ₹35 crore.
The company emphasized its strategic focus on growth areas such as pharmaceuticals (CDMO, peptides), nuclear and thermal power, defense, semiconductors, and critical minerals. The transformation program is expected to yield significant benefits from FY 2028 onwards.
What to do with a filing like this
GMM Pfaudler Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by GMM Pfaudler Limited. Read the original for the full detail.